Glaucoma – Market Access and Reimbursement Insights Report – 2025

Glaucoma Market Access and Reimbursement Insights

Thelansis’s “Glaucoma Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Glaucoma Overview

Glaucoma is a chronic and progressive ocular disease that results in visual field loss due to damage to the optic nerve. The optic nerve is responsible for transmitting visual information from the retina to the brain, and damage to this nerve can cause irreversible vision loss. It can manifest in different forms, including primary (open-angle, normal-tension, angle-closure, and congenital glaucoma) and secondary (neovascular, pigmentary, exfoliation, and uveitic glaucoma). The primary risk factor for the disease is increased intraocular pressure resulting from abnormalities in the eye’s drainage system, which leads to fluid accumulation that damages the optic nerve. Diagnosis of glaucoma requires various tests, including visual acuity tests, pupil dilation, visual field tests, tonometry, optic nerve imaging, gonioscopy, and pachymetry.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Glaucoma – Market Access and Reimbursement Insights Report – 2025